Savara (NASDAQ:SVRA)‘s stock had its “buy” rating reiterated by stock analysts at LADENBURG THALM/SH SH in a note issued to investors on Monday, April 1st, Stock Target Advisor reports. They presently have a $21.00 price objective on the stock. LADENBURG THALM/SH SH’s target price indicates a potential upside of 103.49% from the company’s current price.
A number of other research firms also recently issued reports on SVRA. HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of Savara in a research report on Thursday, December 20th. Canaccord Genuity set a $22.00 target price on shares of Savara and gave the stock a “buy” rating in a research report on Monday, March 25th. Zacks Investment Research upgraded shares of Savara from a “sell” rating to a “hold” rating in a research report on Saturday, March 2nd. Finally, BidaskClub upgraded shares of Savara from a “sell” rating to a “hold” rating in a report on Tuesday, March 12th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $21.17.
NASDAQ:SVRA traded down $0.38 during trading hours on Monday, reaching $10.32. 1,421,600 shares of the company’s stock were exchanged, compared to its average volume of 185,524. The stock has a market capitalization of $383.38 million, a price-to-earnings ratio of -8.00 and a beta of 0.86. Savara has a 12 month low of $6.21 and a 12 month high of $14.06. The company has a debt-to-equity ratio of 0.23, a quick ratio of 15.63 and a current ratio of 15.63.
In other Savara news, insider Jaakko Taneli Jouhikainen sold 25,000 shares of the firm’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $9.03, for a total value of $225,750.00. Following the sale, the insider now directly owns 184,754 shares in the company, valued at approximately $1,668,328.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO David L. Lowrance sold 7,500 shares of the firm’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $9.02, for a total transaction of $67,650.00. Following the completion of the sale, the chief financial officer now owns 2,446 shares in the company, valued at $22,062.92. The disclosure for this sale can be found here. Insiders sold a total of 42,761 shares of company stock worth $385,749 over the last quarter. 6.10% of the stock is currently owned by company insiders.
A number of hedge funds have recently made changes to their positions in SVRA. Point72 Asset Management L.P. bought a new position in Savara during the 3rd quarter valued at about $7,957,000. Sofinnova Ventures Inc raised its stake in shares of Savara by 172.0% in the third quarter. Sofinnova Ventures Inc now owns 698,225 shares of the company’s stock worth $7,793,000 after acquiring an additional 441,533 shares during the last quarter. FMR LLC bought a new position in shares of Savara in the fourth quarter worth about $2,830,000. Vanguard Group Inc raised its stake in shares of Savara by 23.6% in the third quarter. Vanguard Group Inc now owns 1,246,240 shares of the company’s stock worth $13,908,000 after acquiring an additional 238,358 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Savara by 23.6% in the third quarter. Vanguard Group Inc. now owns 1,246,240 shares of the company’s stock worth $13,908,000 after acquiring an additional 238,358 shares during the last quarter. 48.42% of the stock is owned by hedge funds and other institutional investors.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Featured Story: 12b-1 Fees
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.